Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
US FDA investigates Takeda's blood disorder drug after pediatric death - 2Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 3Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- 4African Forests Have Become a Source of Carbon Emissions
- 5The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- Longtime United Launch Alliance CEO Tory Bruno resigns from space company. 'Finished the mission I came to do.'
- Well known SUVs With Low Energy Utilization In 2024
- Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- Met Gala 2026 will celebrate fashion as an 'embodied art form': A guide to the theme, dress code, cochairs and hosting committee of the starry event
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- The most effective method to Begin Your Excursion in Gold Venture
- More charges filed against ex-left-wing RAF member Daniela Klette
